Epistasis of ERAP1 With 4 Major Histocompatibility Complex Class I Alleles in Frontal Fibrosing Alopecia: A Genome-Wide Association Study Meta-Analysis.
Tuntas Rayinda, Nick Dand, Sheila M McSweeney, Evangelos Christou, Chuin Ying Ung, Catherine M Stefanato, David A Fenton, Matthew Harries, Ioulios Palamaras, Alice Tidman, Susan Holmes, Anastasia Koutalopoulou, Michael Ardern-Jones, Manjit Kaur, Sofia Papanikou, Vasiliki Chasapi, Sergio Vañó-Galvan, David Saceda-Corralo, Ana Melián-Olivera, Carlos Azcarraga-Llobet, Alejandro Lobato-Berezo, Mariona Bustamante, Jordi Sunyer, Michela Valeria Rita Starace, Bianca Maria Piraccini, Isabel Pupo Wiss, Maryanne Makredes Senna, Rashmi Singh, Kathrin Hillmann, Varvara Kanti-Schmidt, Ulrike Blume-Peytavi, John A McGrath, Michael A Simpson, Christos Tziotzios
{"title":"Epistasis of ERAP1 With 4 Major Histocompatibility Complex Class I Alleles in Frontal Fibrosing Alopecia: A Genome-Wide Association Study Meta-Analysis.","authors":"Tuntas Rayinda, Nick Dand, Sheila M McSweeney, Evangelos Christou, Chuin Ying Ung, Catherine M Stefanato, David A Fenton, Matthew Harries, Ioulios Palamaras, Alice Tidman, Susan Holmes, Anastasia Koutalopoulou, Michael Ardern-Jones, Manjit Kaur, Sofia Papanikou, Vasiliki Chasapi, Sergio Vañó-Galvan, David Saceda-Corralo, Ana Melián-Olivera, Carlos Azcarraga-Llobet, Alejandro Lobato-Berezo, Mariona Bustamante, Jordi Sunyer, Michela Valeria Rita Starace, Bianca Maria Piraccini, Isabel Pupo Wiss, Maryanne Makredes Senna, Rashmi Singh, Kathrin Hillmann, Varvara Kanti-Schmidt, Ulrike Blume-Peytavi, John A McGrath, Michael A Simpson, Christos Tziotzios","doi":"10.1001/jamadermatol.2024.6434","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Frontal fibrosing alopecia (FFA) is an inflammatory and scarring form of hair loss of increasing prevalence that most commonly affects women. An improved understanding of the genetic basis of FFA will support the identification of pathogenic mechanisms and therapeutic targets.</p><p><strong>Objective: </strong>To identify novel genomic loci at which common genetic variation affects FFA susceptibility and assess nonadditive effects on genetic risk between susceptibility loci.</p><p><strong>Design, setting, and participants: </strong>Four genome-wide association studies were combined using an SE-weighted meta-analysis. Within the major histocompatibility complex (MHC) locus, stepwise conditional analysis was undertaken to determine independently associated classical MHC class I alleles. Statistical tests for epistatic interaction were performed between risk alleles at the MHC and endoplasmic reticulum aminopeptidase 1 (ERAP1) loci.</p><p><strong>Main outcomes and measures: </strong>Genome-wide significant locus associated with FFA and nonadditive effects on genetic risk between susceptibility loci.</p><p><strong>Results: </strong>Of 6668 included patients, there were 1585 European female individuals with FFA and 5083 controls. Genome-wide significant associations were identified at 4 genomic loci, including a novel susceptibility locus at 5q15, and the association signal could be fine-mapped to a single nucleotide substitution (rs10045403) in the 5' untranslated region of ERAP1 (rs10045403; odds ratio, 1.30; 95% CI, 1.19-1.43; P = 3.6 × 10-8). Within the MHC, FFA risk was statistically independently associated with HLA-A*11:01, HLA-A*33:01, HLA-B*07:02, and HLA-B*35:01. FFA risk was affected by genetic variation at the ERAP1 locus only in individuals who carried at least 1 of the MHC class I risk alleles.</p><p><strong>Conclusions and relevance: </strong>In this genome-wide meta-analysis, a supra-additive effect of genetic variation was found that affected peptide trimming and antigen presentation on FFA susceptibility. Patients with FFA may benefit from emerging therapeutic approaches that modulate ERAP-mediated processes.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"310-314"},"PeriodicalIF":11.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822599/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamadermatol.2024.6434","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Importance: Frontal fibrosing alopecia (FFA) is an inflammatory and scarring form of hair loss of increasing prevalence that most commonly affects women. An improved understanding of the genetic basis of FFA will support the identification of pathogenic mechanisms and therapeutic targets.
Objective: To identify novel genomic loci at which common genetic variation affects FFA susceptibility and assess nonadditive effects on genetic risk between susceptibility loci.
Design, setting, and participants: Four genome-wide association studies were combined using an SE-weighted meta-analysis. Within the major histocompatibility complex (MHC) locus, stepwise conditional analysis was undertaken to determine independently associated classical MHC class I alleles. Statistical tests for epistatic interaction were performed between risk alleles at the MHC and endoplasmic reticulum aminopeptidase 1 (ERAP1) loci.
Main outcomes and measures: Genome-wide significant locus associated with FFA and nonadditive effects on genetic risk between susceptibility loci.
Results: Of 6668 included patients, there were 1585 European female individuals with FFA and 5083 controls. Genome-wide significant associations were identified at 4 genomic loci, including a novel susceptibility locus at 5q15, and the association signal could be fine-mapped to a single nucleotide substitution (rs10045403) in the 5' untranslated region of ERAP1 (rs10045403; odds ratio, 1.30; 95% CI, 1.19-1.43; P = 3.6 × 10-8). Within the MHC, FFA risk was statistically independently associated with HLA-A*11:01, HLA-A*33:01, HLA-B*07:02, and HLA-B*35:01. FFA risk was affected by genetic variation at the ERAP1 locus only in individuals who carried at least 1 of the MHC class I risk alleles.
Conclusions and relevance: In this genome-wide meta-analysis, a supra-additive effect of genetic variation was found that affected peptide trimming and antigen presentation on FFA susceptibility. Patients with FFA may benefit from emerging therapeutic approaches that modulate ERAP-mediated processes.
期刊介绍：
JAMA Dermatology is an international peer-reviewed journal that has been in continuous publication since 1882. It began publication by the American Medical Association in 1920 as Archives of Dermatology and Syphilology. The journal publishes material that helps in the development and testing of the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery.
JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. It is published online weekly, every Wednesday, and in 12 print/online issues a year. The mission of the journal is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, with the aim of enabling dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care.
The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. It also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists, aiming to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists.
JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
